The company has asked to make a further submission including an improved patient access scheme. NICE has agreed that the appraisal can be referred back to the Appraisal Committee so that it can consider this new economic case.
The appraisal has been temporarily suspended to allow the company to submit and the Appraisal Committee to consider new evidence on the cost effectiveness of palbociclib with the updated patient access scheme in place.
We will provide an update on timelines for this appraisal as soon as they are available.